
Why shares of Novavax are getting crushed
CBSN
Shares of American biotech company and COVID-19 vaccine maker Novavax slid dramatically as the company slashed its sales forecast due to a slump in demand for it shots.
The company's stock dived 31% Tuesday after it cut its 2022 sales outlook in half.
Novavax's protein-based vaccine was a latecomer to the market: it was only authorized by the Food and Drug Administration for use by adults in the U.S. last month, after a majority of U.S. adults had been vaccinated with Pfizer, Moderna or Johnson & Johnson shots. Only 7,381 Novavax vaccine doses have been administered in the U.S., government data shows.

Americans are continually encouraged to sock away money in a 401(k) or other retirement plan to ensure a comfortable, if not cushy, life in their later years. Yet about half of all U.S. workers in the private sector lack access to an employer-sponsored retirement plan, a huge obstacle in building enough wealth to retire, a recent study finds.

Washington — Kilmar Abrego Garcia, a Salvadoran man who was mistakenly deported back to his home country and then returned to the U.S. for federal prosecution, may remain in federal custody, after his lawyers and prosecutors sparred over whether he would be deported immediately upon his release while awaiting a criminal trial.